CUPem

• Research type

  Research Study

• Full title

  A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary - CUPem

• IRAS ID

  247067

• Contact name

  Harpreet Wasan

• Contact email

  h.wasan@imperial.ac.uk

• Sponsor organisation

  Imperial College London

• Eudract number

  2018-001327-39

• Duration of Study in the UK

  3 years, 11 months, 30 days

• Research summary

  This is A Phase II, Two-Stage, non-randomised, single arm Trial of Pembrolizumab in Cancer of unknown primary (CUP).
  The First Cohort will recruit 20 participants who have had previous treatment and the Second Cohort will recruit 57 participants who have not had previous treatment.
  We are looking to find out whether Pembrolizumab is much better tolerated than conventional chemotherapy in CUP patients and how will this treatment improve their overall survival (OS) and their progression free survival (PFS).

• REC name

  London - Brent Research Ethics Committee

• REC reference

  18/LO/1549

• Date of REC Opinion

  5 Nov 2018

• REC opinion

  Further Information Favourable Opinion